leadf
logo-loader
viewBiocept Inc

Biocept wins Japanese patent for its Primer-Switch technology to detect rare mutations and cancer biomarkers

The patent provides IP protection for the technology, which is useful for the detection of mutations and biomarkers found in tissue, blood, and cerebrospinal fluid

cancer
The patent is the third issued for the Primer-Switch technology as Biocept pursues worldwide patent protection for its technology

Biocept Inc (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests, said Wednesday it has won a Japanese patent for its Primer-Switch technology. 

The patent provides intellectual property protection for the Primer-Switch technology, which is useful for the detection of rare mutations, including cancer biomarkers, found in tissue, blood and cerebrospinal fluid using circulating tumor DNA (ctDNA) analysis through real-time PCR and associated analysis methods, including next-generation sequencing (NGS).

Biocept said the patent is the third issued for the Primer-Switch technology as the company pursues worldwide patent protection for the technology. 

READ: Biocept says health insurer Highmark has made a positive coverage determination on its Target Selector liquid biopsy

The Primer-Switch technology provides a method for specifically enriching patient specimens for oncogene mutations of interest. Additionally, the technology can be used to enhance the performance and specificity of the PCR method, which is the most widely used amplification approach in research and molecular diagnostics, including clinical applications. 

Biocept, based in San Diego, holds certain rights to the Primer-Switch technology within the field of clinical oncology.

"The Primer-Switch detection and amplification platform has the potential to find rare mutations in PCR reactions, which is highly useful when there is a need to detect rare genetic events or when more precise PCR amplification reactions are desired or required," said Biocept CEO Michael Nall in a statement.

"This technology builds upon the ability to detect rare genetic events which is the key target in our Target Selector ctDNA assays. We continue to expand our intellectual property portfolio to protect this method that differentiates Biocept from others in the liquid biopsy space," he added.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

 

 

 

 

 

Quick facts: Biocept Inc

Price: 4.52 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $60.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 09/23/2020

2 min read